Impact of cisplatin dose intensity on human papillomavirus-related and -unrelated locally advanced head and neck squamous cell carcinoma
详细信息 查看全文
- 作者：Anna Spreaficoa ; Shao Hui Huangb ; Wei Xuc ; Roberta Granatad ; Chen-Shin Liub ; John N. Waldronb ; Eric Chena ; Jolie Ringashb ; Andrew Bayleyb ; Kelvin K.W. Chana ; Andrew J. Hopeb ; John Chob ; Albiruni A.R. Razaka ; Aaron Hansena ; Raymond Janga ; Bayardo Perez-Ordoneze ; Ilan Weinrebe ; Paolo Bossid ; Ester Orlandid ; Lisa F. Licitrad ; Yuyao Songc ; Brian O'Sullivanb ; Lillian L. Siua ; John Kimb ; john.kim@rmp.uhn.on.ca" class="auth_mail" title="E-mail the corresponding author
- 关键词：Human papillomavirus ; Head and neck cancer ; Survival ; Chemoradiotherapy ; Cisplatin
- 刊名：European Journal of Cancer
- 出版年：2016
- 出版时间：November 2016
- 年：2016
- 卷：67
- 期：Complete
- 页码：174-182
- 全文大小：768 K
文摘
- class="listitem" id="list_ulist0010">
- class="label">•
Cisplatin dose reduction has different survival impact for human papillomavirus (HPV)-related (HPV+) and HPV-unrelated (HPV−) locally advanced head and neck cancer (LAHNC).
- class="label">•
A survival benefit with cisplatin dose >200 mg/m2 is evident for HPV− LAHNC.
- class="label">•
There was no significant survival difference in various cisplatin doses in HPV+ LAHNC overall.
- class="label">•
There was a trend towards inferior survival with cisplatin ≤200 mg/m2 in HPV+ T4 or N3 subset.